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Abstract
The HeartMate II is a continuous-ﬂow left ventricular assist device that can be explanted from patients after cardiac recovery. We
implanted a HeartMate II in a 21-year-old man who had idiopathic cardiomyopathy. A year later, he developed thyrotoxicosis, presum-
ably secondary to amiodarone administered for ventricular ﬁbrillation. Four months after the diagnosis of thyrotoxicosis, thyroid
hormone levels had returned to normal, and native cardiac function had improved remarkably. After a support period of 24 months,
the HeartMate II was explanted. Six years later, the patient continues to be in New York Heart Association functional Class I.
Amiodarone-induced thyrotoxicosis may have contributed to myocardial recovery.
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The HeartMate II left ventricular assist device (LVAD) (Thoratec
Corporation, Pleasanton, CA, USA) is one of a number of
continuous-ﬂow blood pumps being utilized clinically. We de-
scribe a patient who received a HeartMate II for idiopathic car-
diomyopathy and later required medical management of
amiodarone-induced thyrotoxicosis. The thyrotoxicosis appeared
to accelerate improvement in his native cardiac function, allow-
ing the LVAD to be explanted after 24 months of support.
CASE REPORT
A 21-year-old man was transferred from his community hospital
to our institution for heart failure of 1 month’s duration, with
renal and hepatic dysfunction. On his admission to our hospital,
echocardiography conﬁrmed the presence of global hypokinesia
compatible with idiopathic, chronic heart failure. The left ven-
tricular ejection fraction was 10%. Because of the patient’s de-
teriorating condition, he did not respond to medical therapy, so
a HeartMate II LVAD was implanted in a routine fashion.
Intraoperative transesophageal echocardiography conﬁrmed a
depressed ejection fraction of 10%, with a left ventricular end-
diastolic diameter of 6.1 cm. At the time of implant, a biopsy of
the core showed moderate hypertrophy and interstitial ﬁbrosis
with minimal replacement ﬁbrosis.
Over the next 2 weeks, the patient recovered uneventfully and
became ambulatory. Therapy with beta blockers and
angiotensin-converting enzyme inhibitors was initiated com-
mensurate with his heart failure. Echocardiographical studies
showed adequate left ventricular unloading by the HeartMate II
LVAD. His haemodynamic values remained stable, and he was
discharged home on postimplant Day 35. Thyroid function test
results were normal during this initial admission.
Six months later, the patient fainted while doing yard work.
He regained consciousness and was able to drive to his commu-
nity hospital, where he remained alert and oriented. In the
emergency room, electrocardiography showed ventricular ﬁbril-
lation. Sinus rhythm was restored after cardioversion, and amio-
darone therapy was initiated as a precautionary measure.
Thyroid function tests were not obtained during this admission.
During a follow-up visit to our clinic, 1 year after LVAD im-
plantation (and 4 months after amiodarone initiation), the
patient underwent routine transthoracic echocardiography,
which showed sinus tachycardia (up to 120 bpm) with an ad-
equately decompressed left ventricle and improved ejection
fraction of 40% with LVAD support. Further evaluation revealed
that over the preceding 6 weeks, he had a progressive onset of
weight loss, tremors, heat intolerance, hyperactivity, insomnia
and palpitations. Thyroid tests showed the following values:
thyroid-stimulating hormone, <0.01 mcU/ml; T4, 15.5 mcg/dl;
free T4, 4.2 mcg/dl; T3, 769 ng/dl. A radioactive iodine scan, with
an 81% diffuse uptake at 24 h, conﬁrmed a diagnosis of thyro-
toxicosis (Graves’ disease). The patient was given 12.5 mCi of
radioactive iodine and, later, methimazole.
Over the ensuing 6 months, the patient’s thyroid hormone
levels normalized: T3 decreased to 237 ng/dl, free T4 fell to
1.9 mcg/dl and thyroid-stimulating hormone rose to 0.23 mcU/
ml. During the same period, his myocardial contractility
improved. He underwent right-sided heart catheterization and
dobutamine stress testing with LVAD pump speed reduced to
6000 rpm. Under these conditions, the left ventricular ejection
fraction was normal. Therefore, after a support period of 24
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months, the HeartMate II was explanted via a sub-costal ap-
proach that precluded myocardial biopsy. The patient tolerated
the procedure well and was discharged home 12 days later, on a
regimen of beta blockers and angiotensin-converting enzyme
inhibitors. After device explantation, transthoracic echocardiog-
raphy revealed an ejection fraction of 60%. Six years after LVAD
removal, the patient continues to do well and remains in
New York Heart Association functional Class I, with normal left
ventricular function on echocardiography.
DISCUSSION
This patient developed thyrotoxicosis, a known complication of
amiodarone administration, while being supported by a
HeartMate II LVAD. During the period of thyrotoxicosis, ventricu-
lar function improved dramatically.
Although usually considered deleterious, elevated thyroid
hormone levels may be beneﬁcial to ventricular function in
selected patients. Indeed, Khalife et al. [1] found that thyroid hor-
mones improved left ventricular function in hypothyroid ham-
sters with dilated cardiomyopathy. Using a similar model,
Kuzman et al. [2] showed that thyroid hormones decreased the
left ventricular end-diastolic dimension. In a hypertensive rat
model of heart failure, Thomas et al. [3] found that after adminis-
tration of thyroid hormones, left ventricular systolic wall stress
decreased because of a dose-dependent decrease in the left
ventricular chamber diameter and an increase in wall thickness.
The potentially positive effects of thyroid hormones, including
remodelling and improved haemodynamic status, have also
been observed in rats after a myocardial infarction [4].
Administration of agents capable of causing myocardial hyper-
trophy as a second-phase treatment is not novel in patients with
failing, dilated ventricles that have already undergone reverse re-
modelling after a period of mechanical and pharmacological
unloading. Combined with mechanical left-ventricular assistance,
clenbuterol, a beta 2-adrenergic receptor agonist, has been suc-
cessfully used for myocardial recovery [5]. Thyroid hormone has
also been proposed as an agent to improve cardiac function in
organ donors. In our patient, amiodarone-induced thyrotoxicosis
may have contributed to myocardial recovery.
The role of thyroid hormones in aiding ventricular recovery is
uncertain. Many patients have undergone LVAD removal without
the aid of thyroid or other beta agonist therapy. However,
thyroid hormone therapy and other approaches for treating
dilated cardiomyopathy deserve continued study, particularly in
young patients.
ACKNOWLEDGEMENT
The authors thank Virginia Fairchild, of the Texas Heart Institute’s
Department of Scientiﬁc Publications, for editorial assistance in
preparing this manuscript.
Conﬂict of interest: none declared.
REFERENCES
[1] Khalife WI, Tang YD, Kuzman JA, Thomas TA, Anderson BE, Said S et al.
Treatment of subclinical hypothyroidism reverses ischemia and prevents
myocyte loss and progressive LV dysfunction in hamsters with dilated car-
diomyopathy. Am J Phsyiol Heart Circ Physiol 2005;289:H2409–15.
[2] Kuzman JA, Tang Y, Vogelsang KA, Said S, Anderson BE, Morkin E et al.
Thyroid hormone analog, diiodothyropropionic acid (DITPA), exerts bene-
ﬁcial effects on chamber and cellular remodeling in cardiomyopathic
hamsters. Can J Physiol Pharmacol 2007;85:311–8.
[3] Thomas TA, Kuzman JA, Anderson BE, Andersen SM, Schlenker EH,
Holder MS et al. Thyroid hormones induce unique and potentially bene-
ﬁcial changes in cardiac myocyte shape in hypertensive rats near heart
failure. Am J Phsyiol Heart Circ Physiol 2005;288:H2118–22.
[4] Pantos C, Mourouzis I, Markakis K, Dimopoulos A, Xinaris C, Kokkinos AD
et al. Thyroid hormone attenuates cardiac remodeling and improves
hemodynamics early after acute myocardial infarction in rats. Eur J
Cardiothorac Surg 2007;32:333–9.
[5] Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M et al. Left
ventricular assist device and drug therapy for the reversal of heart failure.
N Engl J Med 2006;355:1873–84.
G.V. Letsou et al. / European Journal of Cardio-Thoracic Surgery574
